



**FLORIDA SOCIETY OF CLINICAL ONCOLOGY FAX BLAST – September 18, 2008**  
**FLASCO WEBSITE: [www.flasco.org](http://www.flasco.org)**

**MESSAGE FROM FLASCO PRESIDENT: Robert Cassell, MD**

FLASCO extends a warm welcome to the following new members:

**Loretta Loftus, MD, MBA, Moffitt Cancer Center – Regular**

**Servillano Dela Cruz, Jr., MD, Citrus Hematology and Oncology Center – Regular**

**Daniel Patterson, MD, Bond Clinic, PA – Regular**

**CLINICAL PRACTICE COMMITTEE: Tom Gaddis, MD, Chairman**

**IV Emend**

The FLASCO Office has been receiving questions regarding IV Emend and denials from FCSO. After our last joint meeting with FCSO in May 2008, the decision made regarding IV EMEND was to **non-cover the IV form** if they could tolerate the PO route. FCSO states that claims are only being paid when the documentation supports that the patient cannot tolerate the PO route of the drug. Denied claims will have to follow the appeals process. FCSO recommended that FLASCO not send in any claim examples since there is nothing for the policy area to research.

**FDA Posts List of Prescription Drugs under Investigation for Safety Problems**

On September 6, the Food and Drug Administration (FDA) published a new list of drugs under investigation for potential safety problems. The list, which will be updated quarterly, includes drugs submitted to the agency's Adverse Events Reporting System. The list identifies each drug and its safety concern, but does not report the severity and frequency of the adverse events. Three drugs on the list, Tykerb, Revlimid and Sandostatin LAR, are used to treat cancer.

For more information, contact ASCO's Cancer Policy and Clinical Affairs Department at 571-483-1670 or [researchpolicy@asco.org](mailto:researchpolicy@asco.org)

**FCSO UPDATES:**

**Payment of Anti-Emetic Drugs Provided with Anti-Cancer Chemotherapy Services - PART A**

The Centers for Medicare & Medicaid Services (CMS) has identified an issue regarding payment for off-label drug usage for the anti-cancer and anti-emetic drugs submitted on a hospital bill as part of a chemotherapy course of treatment. CMS has instructed providers to process for payment services for approved anti-cancer drugs submitted with the appropriate anti-emetic drug code until the implementation of the October 2008 quarterly release for the Medicare common working file (CWF) revised edits.

As of August 25, 2008, First Coast Service Options (FCSO) Inc. is automatically suspending claims receiving CWF edits C7245 or C7247 drugs to location S/MEMET. FCSO is performing a manual review of all the claims with charges for anti-cancer and anti-emetic. Claims that have been submitted correctly will be released for payment. Claims that were not billed correctly will be rejected based on the CWF edits C7245 or C7247 guidelines.

**Action required by providers**

Providers that have received denied charges for off-label drug usage for the anti-cancer and anti-emetic drugs prior to August 25, 2008, may resubmit the claim as an adjustment.

**Revised form CMS-R-131, advanced beneficiary notice (ABN):**

This revised ABN combines the ABN-G and the ABN-L into a single notice, with the same form number (CMS R-131). Effective date was March 1, 2008 with an implementation date of March 1, 2009. For the complete article, please visit: <http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6136.pdf>

## **CMS UPDATES:**

### **Attention Physicians, Non-Physician Practitioners and Group Practices: Information on Reporting Changes to Medicare Enrollment Information**

The Centers for Medicare & Medicaid Services (CMS) has posted three new Fact Sheets on the Medicare Provider Enrollment page, <http://www.cms.hhs.gov/MedicareProviderSupEnroll/>, on the CMS website.

These Fact Sheets list the types of changes that enrolled physicians, non-physician practitioners, and group practices are required to report to Medicare within specific times of occurrence. Non-reporting of changes may adversely affect claims processing, claims payment amounts, and the eligibility of the physician, non-physician practitioner, or group practice to participate in Medicare. The Fact Sheets indicate the Medicare provider enrollment forms that must be used to report the changes, and include information on where to go for assistance.

Links to each Fact Sheet are provided below:

#### **Reporting Responsibilities for Individual Physicians Enrolled in the Medicare Program**

<http://www.cms.hhs.gov/MedicareProviderSupEnroll/Downloads/PhysicianReportingResponsibilities.pdf>

#### **Reporting Responsibilities for Individual Non-Physician Practitioners Enrolled in the Medicare Program**

<http://www.cms.hhs.gov/MedicareProviderSupEnroll/Downloads/Non-PhysicianReportingResponsibilities.pdf>

#### **Reporting Responsibilities for Physician Group Practices Enrolled in the Medicare Program**

<http://www.cms.hhs.gov/MedicareProviderSupEnroll/Downloads/GroupPracticeReportingResponsibilities.pdf>

## **NPPES - Keeping It Safe and Keeping it Updated**

This message is for health care providers, particularly physicians and other practitioners, who have obtained National Provider Identifiers (NPIs) and have records in the National Plan and Provider Enumeration System (NPPES). The Centers for Medicare & Medicaid Services (CMS) recommends that each health care provider, including individual physicians and non-physician practitioners:

- Know and maintain their NPPES User Ids and passwords.
- Reset their NPPES passwords at least once a year. See the NPPES Application Help page regarding the ‘Reset Password’ rules. Those rules indicate the length, format, content and requirements of NPPES passwords.
- Review their NPPES records in order to ensure that the information reflects current and correct information.

### **Maintaining NPPES Account Information for Safety and Accessibility**

Health care providers, including physicians and non-physician practitioners, should maintain their own NPPES account information (i.e., User ID, Password, and Secret Question/Answer) for safety and accessibility purposes.

### **Viewing NPPES Information**

Health care providers, including physicians and non-physician practitioners, can view their NPPES information in one of two ways:

(1) By accessing the NPPES record at <https://nppes.cms.hhs.gov/NPPES/Welcome.do> and following the NPI hyperlink and selecting Login. The user will be prompted to enter the User ID and password that he/she previously created. \*

\* If the health care provider has forgotten the password, enter the User ID and click the “Reset Forgotten Password” button to navigate to the Reset Password Page. If the health care provider enters an incorrect User ID and Password combination three times, the User ID will be disabled. Please contact the NPI Enumerator at 1-800-465-3203 if the account is disabled or if the health care provider has forgotten the User ID.

**OR**

(2) By accessing the NPI Registry at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>. The NPI Registry gives the health care provider an online view of Freedom of Information Act (FOIA)-disclosable NPPES data. The health care provider can search for its information using the name or NPI as the criterion.

### **Updating NPPES Information**

Health care providers, including physicians and non-physician practitioners, can correct, add, or delete information in their NPPES records by accessing their NPPES records at <https://nppes.cms.hhs.gov/NPPES/Welcome.do> and following the NPI hyperlink and selecting Login. The user will be prompted to enter the User ID and password that he/she previously created.

*Please note:* Required information cannot be deleted from an NPPES record; however, required information can be changed/updated to ensure that NPPES captures the correct information. Certain information is inaccessible via the web, thus requiring the change/update to be made via paper application. The paper NPI Application/Update Form can be downloaded and printed at <http://www.cms.hhs.gov/cmsforms/downloads/CMS10114.pdf>.

### **Need More Information?**

Providers can apply for an NPI online at <https://nppes.cms.hhs.gov> or can call the NPI enumerator to request a paper application at 1-800-465-3203. Having trouble viewing any of the URLs in this message? If so, try to cut and paste any URL in this message into your web browser to view the intended information.

Note: All current and past CMS NPI communications are available by clicking "CMS Communications" in the left column of the [www.cms.hhs.gov/NationalProvIdentStand](http://www.cms.hhs.gov/NationalProvIdentStand) CMS webpage.

### **MLM MATTERS:**

#### **New:**

MM6183 – Limitation on Recoupment (935) for Provider, Physicians and Suppliers Overpayments  
<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6183.pdf>

MM6163 – Smoking and Tobacco Use Cessation Counseling Billing Update for Comprehensive Outpatient Rehabilitation Facilities (CORFs) and Outpatient Physical Therapy Providers (OPTs)  
<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6163.pdf>

MM6175 – October 2008 Quarterly Average Sales Price (ASP) Medicare Part B Drug Pricing Files and Revisions to Prior Quarterly Pricing Files <http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6175.pdf>

MM6093 – National Provider Identifier (NPI) for Secondary Providers  
<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6093.pdf>

#### **Rescinded:**

MM6012 – Revision to the Inpatient Prospective Payment System (IPPS) Post Acute Transfer Policy for Discharges/Transfers to Home Under Care of an Organized Home Health Service Organization in Anticipation of Covered Skilled Care

### **FDA UPDATES:**

#### **Genentech Updates Pml Warnings For Rituxan**

Genentech has updated the labeling of Rituxan (rituximab) to report a fatal case of progressive multifocal leukoencephalopathy (PML) in a rheumatoid arthritis (RA) patient. Read the entire 2008 MedWatch Safety Summary, including a link to the manufacturer's Dear Healthcare Professional Letter and updated prescribing information for Rituxan regarding the above issue at: <http://www.fda.gov/medwatch/safety/2008/safety08.htm#Rituxan>

### **EDUCATIONAL OPPORTUNITIES:**

#### **Oncotype DX -New HER2 Score Web Conference – Genomic Health**

Gary Palmer, MD, JD, MBA, MPH • Thursday, September 18 • 8 pm EDT

Gary Palmer, MD, JD, MBA, MPH • Friday, October 3 • 12 pm EDT

The following is Pathology focused:

Rick Baehner, MD • Tuesday, September 30 • 1 pm EDT

To register: **Physicians may register by contacting Nikki Detore at 1-866-984-5114 or ndetore@envisioncomm.net**

**“Treatment Modalities for Metastatic Androgen-Independent Prostate Cancer: A Multidisciplinary Approach”.**

Tuesday, September 23<sup>rd</sup>, 2008 – LIVE Web-cast at two Locations in Florida– 6:00 P.M. at Roy’s Restaurant, 4342 W. Boy Scout Road, Tampa, FL 33607, and 6:00 P.M. at Marriott Fort Lauderdale North 6650 North Andrews Avenue, Ft. Lauderdale, FL 33309. **Target Audience:** Urologists, Medical Oncologists, ARNP’s, and PA’s. Please register to attend a specific location or attend remotely via our Web Conference at <http://medtrendintl.com/invite/mtt> or 1-888-364-5228

**Webcast Series On Advanced Rcc And Imatinib-Resistant Gist**

Pfizer is sponsoring both Oncologist and Nurse Webcast on Advanced RCC and Imatinib-Resistant GIST. There are multiple dates for Oncologist: Sept. 24, 25, 30, OCT. 22, 28, Nov.5, and 19. Nurse dates are: Sept. 17, 19, 22, Nov. 11 and 18. You may register at: [www.PfizerOncology.com/webcast](http://www.PfizerOncology.com/webcast) or call the registration line at 1-877-426-3662. Enter Promotion Code: DR276W

**Fourth Annual Oncology Congress:**

FLASCO is one of the co-sponsors of the Fourth Annual Oncology Congress which will be held September 25-28, 2008, at the Hilton San Francisco. If you are interested in receiving a copy of the Final Program Information please contact the FLASCO Executive Director and she will be glad to send you a copy.

**CORPORATE MEMBERSHIP/SPONSORSHIP: (January 1 – December 31, 2008)**

FLASCO Members extends a big thanks to all of our 2008 Corporate Members/Sponsors

**PLATINUM**

Astra Zeneca  
Bayer/Onyx  
Cephalon Oncology  
Eli Lilly  
Oncology Supply/ION  
Sanofi-Aventis  
OPR  
Pharmion  
AMGEN  
Genentech  
Abraxis Oncology.  
Ortho Biotech  
GlaxoSmithKline

**GOLD**

Celgene  
Genomic Health  
Novartis  
Pfizer  
Roche  
Bristol Myers Squibb  
Wyeth

**SILVER**

Eisai, Inc.  
US Oncology  
ImClone Systems  
OSI Pharmaceuticals  
Millennium Pharmaceuticals, Inc.

**BRONZE**

Boehringer Ingelheim  
Pharmaceuticals, Inc.  
Alexion  
Genzyme

**FLASCO EVENTS:**

**November 7-8, 2008** – FLASCO Fall Meeting – Tampa Airport Marriott Hotel

**January 17-18, 2009** – Clinical Breakthroughs & Challenges in Hematologic Malignancies – Grand Floridian Resort – Lake Buena Vista

**February 6 & 7, 2009** – Highlights of ASH - Miami

**February 27 & 28, 2009** – FLASCO Spring Meeting – Marriott Sawgrass – Jacksonville

**March 20, 2009** – Statewide PA & NP Conference, Moffitt Cancer Center - Tampa

**FLASCO Contact Information:** Dorothy Green Phillips, Executive Director -3709W. Jetton Ave., Tampa, Florida 33629 - Tel: 800.444.1410, Ext. 4410 - Cell Phone: 813.294.2620 - Fax: 813.349-4410 or 813.349.4472  
Email: [Dorothy.Green@cancer.org](mailto:Dorothy.Green@cancer.org)

**OTHER EVENTS:**

September 17-20, 2008 – ACCC 25<sup>th</sup> National Oncology Economic Conference – San Francisco, California

September 19-20, 2008 - Annual ASCO/ASH/SGO Meeting of the Hematology/Oncology CAC Network

September 25-28, 2008 - Oncology Congress - the Hilton San Francisco

October 19-22, 2008 – MGMA 2008 Annual Conference – San Diego

October 23<sup>rd</sup> & 24<sup>th</sup>, 2008 – ASCO State Leadership Conference – Alexandria, VA

December 6-9, 2008 – ASH Annual meeting – San Francisco

February 26-28, 2009 – ASCO - GU Symposium, Orlando World Center Marriott

March 22-24, 2009 - 2009 AOHA Assembly Conference – Los Angeles, California